APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Coagulation Factor VIII

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Selected research

Market Structure

Global Human Coagulation Factor VIII Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

9 January 2026193 pages

Choose your research edition.

Industry ResearchHuman Coagulation Factor VIII Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Coagulation Factor VIII Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Human Coagulation Factor VIII Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Coagulation Factor VIII Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Coagulation Factor VIII Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.

This report provides an overview of the global Human Coagulation Factor VIII market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Human Coagulation Factor VIII and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Coagulation Factor VIII sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Coagulation Factor VIII market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Coagulation Factor VIII Segment by Company

Shire (Baxter)

Bayer

CSL

Pfizer

Grifols

Biogen

Octapharma

NovoNordisk

Greencross

Kedrion

BPL

Hualan Bio

RAAS

Human Coagulation Factor VIII Segment by Type

Recombinant Factor VIII

Plasma-derived Factor VIII

Human Coagulation Factor VIII Segment by Application

Hemophilia A

Spontanous / Trauma

Surgical

Other

Human Coagulation Factor VIII Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor VIII market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor VIII and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor VIII.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Coagulation Factor VIII market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Coagulation Factor VIII Industry Trends Table 2. Human Coagulation Factor VIII Industry Drivers Table 3. Human Coagulation Factor VIII Industry Opportunities and Challenges Table 4. Human Coagulation Factor VIII Industry Restraints Table 5. Global Human Coagulation Factor VIII Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Coagulation Factor VIII Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Coagulation Factor VIII Sales by Manufacturers (K Bottles) & (2021-2026) Table 8. Global Human Coagulation Factor VIII Sales Market Share by Manufacturers Table 9. Global Human Coagulation Factor VIII Average Sales Price (USD/Bottle) of Manufacturers (2021-2026) Table 10. Global Human Coagulation Factor VIII Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Coagulation Factor VIII Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Coagulation Factor VIII Manufacturers, Product Type & Application Table 13. Global Human Coagulation Factor VIII Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Coagulation Factor VIII by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Recombinant Factor VIII Table 17. Major Manufacturers of Plasma-derived Factor VIII Table 18. Global Human Coagulation Factor VIII Sales by Type 2021 VS 2025 VS 2032 (K Bottles) Table 19. Global Human Coagulation Factor VIII Sales by Type (2021-2026) & (K Bottles) Table 20. Global Human Coagulation Factor VIII Sales by Type (2027-2032) & (K Bottles) Table 21. Global Human Coagulation Factor VIII Sales Market Share by Type (2021-2026) Table 22. Global Human Coagulation Factor VIII Sales Market Share by Type (2027-2032) Table 23. Global Human Coagulation Factor VIII Revenue by Type 2021 VS 2025 VS 2032 (K Bottles) Table 24. Global Human Coagulation Factor VIII Revenue by Type (2021-2026) & (K Bottles) Table 25. Global Human Coagulation Factor VIII Revenue by Type (2027-2032) & (K Bottles) Table 26. Global Human Coagulation Factor VIII Revenue Market Share by Type (2021-2026) Table 27. Global Human Coagulation Factor VIII Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hemophilia A Table 29. Major Manufacturers of Spontanous / Trauma Table 30. Major Manufacturers of Surgical Table 31. Major Manufacturers of Other Table 32. Global Human Coagulation Factor VIII Sales by Application 2021 VS 2025 VS 2032 (K Bottles) Table 33. Global Human Coagulation Factor VIII Sales by Application (2021-2026) & (K Bottles) Table 34. Global Human Coagulation Factor VIII Sales by Application (2027-2032) & (K Bottles) Table 35. Global Human Coagulation Factor VIII Sales Market Share by Application (2021-2026) Table 36. Global Human Coagulation Factor VIII Sales Market Share by Application (2027-2032) Table 37. Global Human Coagulation Factor VIII Revenue by Application 2021 VS 2025 VS 2032 (K Bottles) Table 38. Global Human Coagulation Factor VIII Revenue by Application (2021-2026) & (K Bottles) Table 39. Global Human Coagulation Factor VIII Revenue by Application (2027-2032) & (K Bottles) Table 40. Global Human Coagulation Factor VIII Revenue Market Share by Application (2021-2026) Table 41. Global Human Coagulation Factor VIII Revenue Market Share by Application (2027-2032) Table 42. Global Human Coagulation Factor VIII Sales by Region: 2021 VS 2025 VS 2032 (K Bottles) Table 43. Global Human Coagulation Factor VIII Sales by Region (2021-2026) & (K Bottles) Table 44. Global Human Coagulation Factor VIII Sales Market Share by Region (2021-2026) Table 45. Global Human Coagulation Factor VIII Sales Forecasted by Region (2027-2032) & (K Bottles) Table 46. Global Human Coagulation Factor VIII Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Bottles) Table 48. North America Human Coagulation Factor VIII Sales by Country (2021-2026) & (K Bottles) Table 49. North America Human Coagulation Factor VIII Sales by Country (2027-2032) & (K Bottles) Table 50. Europe Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Bottles) Table 51. Europe Human Coagulation Factor VIII Sales by Country (2021-2026) & (K Bottles) Table 52. Europe Human Coagulation Factor VIII Sales by Country (2027-2032) & (K Bottles) Table 53. Asia Pacific Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Bottles) Table 54. Asia Pacific Human Coagulation Factor VIII Sales by Country (2021-2026) & (K Bottles) Table 55. Asia Pacific Human Coagulation Factor VIII Sales by Country (2027-2032) & (K Bottles) Table 56. South America, Middle East and Africa Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Bottles) Table 57. South America, Middle East and Africa Human Coagulation Factor VIII Sales by Country (2021-2026) & (K Bottles) Table 58. South America, Middle East and Africa Human Coagulation Factor VIII Sales by Country (2027-2032) & (K Bottles) Table 59. Global Human Coagulation Factor VIII Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Human Coagulation Factor VIII Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Human Coagulation Factor VIII Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Human Coagulation Factor VIII Revenue Market Share by Region (2021-2026) Table 63. Global Human Coagulation Factor VIII Revenue Market Share by Region (2027-2032) Table 64. Shire (Baxter) Company Information Table 65. Shire (Baxter) Business Overview Table 66. Shire (Baxter) Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Shire (Baxter) Human Coagulation Factor VIII Product Portfolio Table 68. Shire (Baxter) Recent Development Table 69. Bayer Company Information Table 70. Bayer Business Overview Table 71. Bayer Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Bayer Human Coagulation Factor VIII Product Portfolio Table 73. Bayer Recent Development Table 74. CSL Company Information Table 75. CSL Business Overview Table 76. CSL Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. CSL Human Coagulation Factor VIII Product Portfolio Table 78. CSL Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Human Coagulation Factor VIII Product Portfolio Table 83. Pfizer Recent Development Table 84. Grifols Company Information Table 85. Grifols Business Overview Table 86. Grifols Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Grifols Human Coagulation Factor VIII Product Portfolio Table 88. Grifols Recent Development Table 89. Biogen Company Information Table 90. Biogen Business Overview Table 91. Biogen Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Biogen Human Coagulation Factor VIII Product Portfolio Table 93. Biogen Recent Development Table 94. Octapharma Company Information Table 95. Octapharma Business Overview Table 96. Octapharma Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Octapharma Human Coagulation Factor VIII Product Portfolio Table 98. Octapharma Recent Development Table 99. NovoNordisk Company Information Table 100. NovoNordisk Business Overview Table 101. NovoNordisk Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. NovoNordisk Human Coagulation Factor VIII Product Portfolio Table 103. NovoNordisk Recent Development Table 104. Greencross Company Information Table 105. Greencross Business Overview Table 106. Greencross Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Greencross Human Coagulation Factor VIII Product Portfolio Table 108. Greencross Recent Development Table 109. Kedrion Company Information Table 110. Kedrion Business Overview Table 111. Kedrion Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Kedrion Human Coagulation Factor VIII Product Portfolio Table 113. Kedrion Recent Development Table 114. BPL Company Information Table 115. BPL Business Overview Table 116. BPL Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. BPL Human Coagulation Factor VIII Product Portfolio Table 118. BPL Recent Development Table 119. Hualan Bio Company Information Table 120. Hualan Bio Business Overview Table 121. Hualan Bio Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Hualan Bio Human Coagulation Factor VIII Product Portfolio Table 123. Hualan Bio Recent Development Table 124. RAAS Company Information Table 125. RAAS Business Overview Table 126. RAAS Human Coagulation Factor VIII Sales (K Bottles), Price (USD/Bottle), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. RAAS Human Coagulation Factor VIII Product Portfolio Table 128. RAAS Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Human Coagulation Factor VIII Distributors List Table 132. Human Coagulation Factor VIII Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Human Coagulation Factor VIII Product Image Figure 2. Global Human Coagulation Factor VIII Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Coagulation Factor VIII Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Coagulation Factor VIII Sales (2021-2032) & (K Bottles) Figure 5. Global Human Coagulation Factor VIII Average Price (USD/Bottle) & (2021-2032) Figure 6. Global Top 5 and 10 Human Coagulation Factor VIII Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Recombinant Factor VIII Image Figure 9. Plasma-derived Factor VIII Image Figure 10. Global Human Coagulation Factor VIII Sales by Type (2021 VS 2025 VS 2032) & (K Bottles) Figure 11. Global Human Coagulation Factor VIII Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Human Coagulation Factor VIII Sales Market Share by Type (2021-2032) Figure 13. Global Human Coagulation Factor VIII Revenue by Type (2021 VS 2025 VS 2032) & (K Bottles) Figure 14. Global Human Coagulation Factor VIII Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Human Coagulation Factor VIII Revenue Market Share by Type (2021-2032) Figure 16. Hemophilia A Image Figure 17. Spontanous / Trauma Image Figure 18. Surgical Image Figure 19. Other Image Figure 20. Global Human Coagulation Factor VIII Sales by Application (2021 VS 2025 VS 2032) & (K Bottles) Figure 21. Global Human Coagulation Factor VIII Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Human Coagulation Factor VIII Sales Market Share by Application (2021-2032) Figure 23. Global Human Coagulation Factor VIII Revenue by Application (2021 VS 2025 VS 2032) & (K Bottles) Figure 24. Global Human Coagulation Factor VIII Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Human Coagulation Factor VIII Revenue Market Share by Application (2021-2032) Figure 26. North America Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 27. North America Human Coagulation Factor VIII Sales Market Share by Country (2021-2032) Figure 28. U.S. Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 29. Canada Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 30. Mexico Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 31. Europe Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 32. Europe Human Coagulation Factor VIII Sales Market Share by Country (2021-2032) Figure 33. Germany Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 34. France Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 35. U.K. Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 36. Italy Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 37. Netherlands Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 38. Asia Pacific Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 39. Asia Pacific Human Coagulation Factor VIII Sales Market Share by Country (2021-2032) Figure 40. China Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 41. Japan Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 42. South Korea Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 43. Southeast Asia Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 44. India Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 45. Australia Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 46. South America, Middle East and Africa Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 47. South America, Middle East and Africa Human Coagulation Factor VIII Sales Market Share by Country (2021-2032) Figure 48. Brazil Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 49. South Africa Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 50. Saudi Arabia Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 51. Turkey Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 52. Argentina Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 53. UAE Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 54. Egypt Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 55. Chile Human Coagulation Factor VIII Sales and Growth Rate (2021-2032) & (K Bottles) Figure 56. Global Human Coagulation Factor VIII Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Human Coagulation Factor VIII Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Human Coagulation Factor VIII Revenue (2021-2032) & (US$ Million) Figure 59. North America Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Human Coagulation Factor VIII Revenue (2021-2032) & (US$ Million) Figure 61. Europe Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Human Coagulation Factor VIII Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Human Coagulation Factor VIII Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Human Coagulation Factor VIII Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Human Coagulation Factor VIII Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Factor VIII
  • Plasma-derived Factor VIII
Applications
  • Hemophilia A
  • Spontanous / Trauma
  • Surgical
  • Other
Companies covered
  • Shire (Baxter)
  • Bayer
  • CSL
  • Pfizer
  • Grifols
  • Biogen
  • Octapharma
  • NovoNordisk
  • Greencross
  • Kedrion
  • BPL
  • Hualan Bio
  • RAAS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Coagulation Factor VIII Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Coagulation Factor VIII Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Coagulation Factor VIII Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Coagulation Factor VIII Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Coagulation Factor VIII Market Dynamics
  1. 2.1 Human Coagulation Factor VIII Industry Trends
  2. 2.2 Human Coagulation Factor VIII Industry Drivers
  3. 2.3 Human Coagulation Factor VIII Industry Opportunities and Challenges
  4. 2.4 Human Coagulation Factor VIII Industry Restraints
3 Human Coagulation Factor VIII Market by Manufacturers
  1. 3.1 Global Human Coagulation Factor VIII Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Coagulation Factor VIII Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Coagulation Factor VIII Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Coagulation Factor VIII Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Coagulation Factor VIII Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Coagulation Factor VIII Manufacturers, Product Type & Application
  7. 3.7 Global Human Coagulation Factor VIII Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Coagulation Factor VIII Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Coagulation Factor VIII Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Coagulation Factor VIII Tier 1, Tier 2, and Tier 3
4 Human Coagulation Factor VIII Market by Type
  1. 4.1 Human Coagulation Factor VIII Type Introduction
  2. 4.1.1 Recombinant Factor VIII
  3. 4.1.2 Plasma-derived Factor VIII
  4. 4.2 Global Human Coagulation Factor VIII Sales by Type
  5. 4.2.1 Global Human Coagulation Factor VIII Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Coagulation Factor VIII Sales by Type (2021-2032)
  7. 4.2.3 Global Human Coagulation Factor VIII Sales Market Share by Type (2021-2032)
  8. 4.3 Global Human Coagulation Factor VIII Revenue by Type
  9. 4.3.1 Global Human Coagulation Factor VIII Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Coagulation Factor VIII Revenue by Type (2021-2032)
  11. 4.3.3 Global Human Coagulation Factor VIII Revenue Market Share by Type (2021-2032)
5 Human Coagulation Factor VIII Market by Application
  1. 5.1 Human Coagulation Factor VIII Application Introduction
  2. 5.1.1 Hemophilia A
  3. 5.1.2 Spontanous / Trauma
  4. 5.1.3 Surgical
  5. 5.1.4 Other
  6. 5.2 Global Human Coagulation Factor VIII Sales by Application
  7. 5.2.1 Global Human Coagulation Factor VIII Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Coagulation Factor VIII Sales by Application (2021-2032)
  9. 5.2.3 Global Human Coagulation Factor VIII Sales Market Share by Application (2021-2032)
  10. 5.3 Global Human Coagulation Factor VIII Revenue by Application
  11. 5.3.1 Global Human Coagulation Factor VIII Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Human Coagulation Factor VIII Revenue by Application (2021-2032)
  13. 5.3.3 Global Human Coagulation Factor VIII Revenue Market Share by Application (2021-2032)
6 Global Human Coagulation Factor VIII Sales by Region
  1. 6.1 Global Human Coagulation Factor VIII Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Coagulation Factor VIII Sales by Region (2021-2032)
  3. 6.2.1 Global Human Coagulation Factor VIII Sales by Region (2021-2026)
  4. 6.2.2 Global Human Coagulation Factor VIII Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Coagulation Factor VIII Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Coagulation Factor VIII Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Coagulation Factor VIII Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Coagulation Factor VIII Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Coagulation Factor VIII Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Coagulation Factor VIII Revenue by Region
  1. 7.1 Global Human Coagulation Factor VIII Revenue by Region
  2. 7.1.1 Global Human Coagulation Factor VIII Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Coagulation Factor VIII Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Coagulation Factor VIII Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Coagulation Factor VIII Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Coagulation Factor VIII Revenue (2021-2032)
  8. 7.2.2 North America Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Coagulation Factor VIII Revenue (2021-2032)
  11. 7.3.2 Europe Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Coagulation Factor VIII Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Coagulation Factor VIII Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Coagulation Factor VIII Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Shire (Baxter)
  2. 8.1.1 Shire (Baxter) Company Information
  3. 8.1.2 Shire (Baxter) Business Overview
  4. 8.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shire (Baxter) Human Coagulation Factor VIII Product Portfolio
  6. 8.1.5 Shire (Baxter) Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Human Coagulation Factor VIII Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 CSL
  14. 8.3.1 CSL Company Information
  15. 8.3.2 CSL Business Overview
  16. 8.3.3 CSL Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSL Human Coagulation Factor VIII Product Portfolio
  18. 8.3.5 CSL Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Human Coagulation Factor VIII Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Grifols
  26. 8.5.1 Grifols Company Information
  27. 8.5.2 Grifols Business Overview
  28. 8.5.3 Grifols Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Grifols Human Coagulation Factor VIII Product Portfolio
  30. 8.5.5 Grifols Recent Developments
  31. 8.6 Biogen
  32. 8.6.1 Biogen Company Information
  33. 8.6.2 Biogen Business Overview
  34. 8.6.3 Biogen Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biogen Human Coagulation Factor VIII Product Portfolio
  36. 8.6.5 Biogen Recent Developments
  37. 8.7 Octapharma
  38. 8.7.1 Octapharma Company Information
  39. 8.7.2 Octapharma Business Overview
  40. 8.7.3 Octapharma Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Octapharma Human Coagulation Factor VIII Product Portfolio
  42. 8.7.5 Octapharma Recent Developments
  43. 8.8 NovoNordisk
  44. 8.8.1 NovoNordisk Company Information
  45. 8.8.2 NovoNordisk Business Overview
  46. 8.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NovoNordisk Human Coagulation Factor VIII Product Portfolio
  48. 8.8.5 NovoNordisk Recent Developments
  49. 8.9 Greencross
  50. 8.9.1 Greencross Company Information
  51. 8.9.2 Greencross Business Overview
  52. 8.9.3 Greencross Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Greencross Human Coagulation Factor VIII Product Portfolio
  54. 8.9.5 Greencross Recent Developments
  55. 8.10 Kedrion
  56. 8.10.1 Kedrion Company Information
  57. 8.10.2 Kedrion Business Overview
  58. 8.10.3 Kedrion Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kedrion Human Coagulation Factor VIII Product Portfolio
  60. 8.10.5 Kedrion Recent Developments
  61. 8.11 BPL
  62. 8.11.1 BPL Company Information
  63. 8.11.2 BPL Business Overview
  64. 8.11.3 BPL Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BPL Human Coagulation Factor VIII Product Portfolio
  66. 8.11.5 BPL Recent Developments
  67. 8.12 Hualan Bio
  68. 8.12.1 Hualan Bio Company Information
  69. 8.12.2 Hualan Bio Business Overview
  70. 8.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hualan Bio Human Coagulation Factor VIII Product Portfolio
  72. 8.12.5 Hualan Bio Recent Developments
  73. 8.13 RAAS
  74. 8.13.1 RAAS Company Information
  75. 8.13.2 RAAS Business Overview
  76. 8.13.3 RAAS Human Coagulation Factor VIII Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 RAAS Human Coagulation Factor VIII Product Portfolio
  78. 8.13.5 RAAS Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Coagulation Factor VIII Value Chain Analysis
  2. 9.1.1 Human Coagulation Factor VIII Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Coagulation Factor VIII Production Mode & Process
  6. 9.2 Human Coagulation Factor VIII Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Coagulation Factor VIII Distributors
  9. 9.2.3 Human Coagulation Factor VIII Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst